In a PO-induced hyperuricemia mouse model, reduction of serum urate by treatment with the XOD inhibitor N-(9,10-anthraquinone-2-yl-carbonyl), downregulates Glut9 protein expression and upregulates Oat1 and Oat3 protein expression, resulting in decrease in the levels of TNF-α, IL-6, and other inflammatory factors in the serum and kidney of mice and inhibition of NLRP3 pathway-mediated inflammation (Gao et al., 2022). The gene discussed is SLC22A6; the disease is hyperuricemia.